IP Library › Granted Patent US 8,222,229
Granted Patent B2
US 8,222,229 · App. 10/533,538 · Granted Jul 17, 2012

Peritoneal dialysis method

Assignee: Kowa Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,222,229
App. No.
10/533,538
Granted
Jul 17, 2012
Kind
B2
Abstract

A peritoneal dialysate containing adenosine triphosphate or a salt thereof, and a peritoneal dialysis method using the dialysate. The peritoneal dialysate is safe and causes less peritoneal injuries even when employed in peritoneal dialysis over a long period of time.

Claims (47)

1. A peritoneal dialysis method comprising:

administering into the peritoneum of a patient having uremia or renal failure a dialysate comprising adenosine triphosphate or a salt thereof; and subsequently

discharging said dialysate from the peritoneum.

2. The peritoneal dialysis method of claim 1 ,

wherein said patient is suffering from a renal disease, and

said dialysate is administered intraperitoneally via a catheter implanted in the peritoneal cavity.

3. The peritoneal dialysis method of claim 1 or 2 , wherein the concentration of adenosine triphosphate or a salt thereof in the dialysate ranges from 10 to 5,000 μM.

4. The peritoneal dialysis method of claim 1 or 2 , wherein the dialysate further comprises glucose and an electrolyte.

5. The peritoneal dialysis method of claim 4 , wherein the glucose level ranges from 1,000 to 4,000 mg/dL.

6. The peritoneal dialysis method of claim 1 , further comprising:

administering a dialysate containing a high level of glucose into a patient suffering a renal disease through a catheter implanted in the peritoneal cavity after administering said dialysate containing adenosine triphosphate or a salt thereof and a physiological level of glucose.

7. The peritoneal dialysis method of claim 6 , wherein the physiological glucose level ranges from 0.08 to 0.16% (w/v) and the high glucose level ranges from 1,000 to 4,000 mg/dL.

8. A method for treating peritoneal injury in a subject having uremia and undergoing repeated dialysis with a peritoneal dialysate containing glucose, comprising administering an effective amount of adenosine triphosphate or a salt thereof into the peritoneum of said subject.

9. A treating method for peritoneal cell injury caused by sugar, comprising administering into the peritoneum of a subject in need thereof an effective amount of adenosine triphosphate or a salt thereof to a subject in need thereof.

10. The method as described in claim 9 , wherein the cell injury caused by sugar is peritoneal mesothelial cell injury caused by glucose.

11. A peritoneal dialysis method comprising:

administering into the peritoneal cavity of a subject having uremia an effective amount of a composition comprising adenosine triphosphate or a salt thereof; and subsequently

discharging said dialysate from the peritoneal cavity.

12. The method of claim 11 , wherein said composition further comprises glucose and electrolytes.

13. The method of claim 11 , wherein said composition contains:

10 to 5,000 μM of adenosine triphosphate or a salt thereof,

1,000 to 4,000 mg/dL glucose,

100 to 200 mEq/L Na + ,

4 to 5 mEq/L Ca 2+ ,

1 to 2 mEq/L Mg 2+ , and

80 to 120 mEq/L Cl − .

14. The method of claim 13 , wherein said composition also contains 30 to 50 mEq/L of an organic acid.

15. The method of claim 13 , wherein said composition also contains 30 to 50 mEq/L of lactic acid.

16. The method of claim 11 , wherein said composition has an osmotic pressure ranging between 300 and 700 mOsm/L.

17. The method of claim 11 , wherein said subject has renal failure.

18. The method of claim 11 , wherein said subject has peritoneal mesothelial cell injuries caused by exposure to high levels of sugar.

19. The method of claim 11 , wherein said subject has hardening of the peritoneum or peritonitis.

20. The method of claim 11 , wherein said subject has sclerotic encysted peritonitis or intractable prolonged peritonitis.

21. The method of claim 8 , comprising administering a solution containing:

adenosine triphosphate or a salt thereof,

1,000 to 4,000 mg/dL glucose, and

electrolytes.

22. The method of claim 9 , comprising administering a solution containing:

adenosine triphosphate or a salt thereof,

1,000 to 4,000 mg/dL glucose, and

electrolytes.

23. A peritoneal dialysis method comprising:

administering into the peritoneal cavity of a patient in need of dialysis a dialysate comprising adenosine triphosphate or a salt thereof; and subsequently

discharging said dialysate from the peritoneal cavity.

24. The peritoneal dialysis method of claim 23 , further comprising a step of adding adenosine triphosphate to a conventional peritoneal dialysis solution that does not contain adenosine triphosphate to produce a dialysate and then administering said dialysate to a patient in need thereof.

25. The peritoneal dialysis method of claim 23 , wherein the dialysate contains 10 to 5,000 μM of adenosine triphosphate.

26. The peritoneal dialysis method of claim 23 , wherein said patient has hardening of the peritoneum or peritonitis or other damage to the peritoneum characterized by mesothelial cell injury caused by prior exposure to a peritoneal dialysis solution that does not contain adenosine triphosphate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2005
From: KIRIBAYASHI, KEI; YORIOKA, NORIAKI
To: KOWA CO., LTD.
Reel/Frame 016579/0635 →
Continuity (2)
Provisional Application 60427980 · Nov 21, 2002
Related Publication 20060019925A1 · Jan 26, 2006